The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design - PubMed (original) (raw)
doi: 10.1016/j.ahj.2013.08.024. Epub 2013 Oct 10.
L Jesús Jiménez-Borreguero, José L Peñalvo, José M Ordovás, Agustín Mocoroa, Leticia Fernández-Friera, Martín Laclaustra, Laura García, Jesús Molina, José M Mendiguren, Beatriz López-Melgar, Vicente Martínez de Vega, Juan C Alonso-Farto, Eliseo Guallar, Henrik Sillesen, James H F Rudd, Zahi A Fayad, Borja Ibañez, Ginés Sanz, Valentín Fuster
Affiliations
- PMID: 24268213
- DOI: 10.1016/j.ahj.2013.08.024
The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design
Antonio Fernández-Ortiz et al. Am Heart J. 2013 Dec.
Abstract
Background: The presence of subclinical atherosclerosis is a likely predictor of cardiovascular events; however, factors associated with the early stages and progression of atherosclerosis are poorly defined.
Objective: The PESA study examines the presence of subclinical atherosclerosis by means of noninvasive imaging and prospectively analyzes the determinants associated with its development and progression in a middle-aged population.
Methods: The PESA study is an observational, longitudinal and prospective cohort study in a target population of 4000 healthy subjects (40-54 years old, 35% women) based in Madrid (Spain). Recruitment began in June 2010 and will be completed by the end of 2013. Baseline examination consists of (1) assessment for cardiovascular risk factors (including lifestyle and psychosocial factors); (2) screening for subclinical atherosclerosis using 2D/3D ultrasound in carotid, abdominal aorta and iliofemoral arteries, and coronary artery calcium score (CACS) by computed tomography; and (3) blood sampling for determination of traditional risk factors, advanced "omics" and biobanking. In addition, a subgroup of 1300 participants with evidence of atherosclerosis on 2D/3D ultrasound or CACS will undergo a combined (18)F-fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging ((18)FDG PET/MRI) study of carotid and iliofemoral arteries. Follow-up at 3 and 6 years will include a repetition of baseline measurements, except for the (18)FDG PET/MRI study, which will be repeated at 6 years.
Conclusions: The PESA study is expected to identify new imaging and biological factors associated with the presence and progression of atherosclerosis in asymptomatic people and will help to establish a more personalized management of medical care.
Trial registration: ClinicalTrials.gov NCT01410318.
© 2013.
Similar articles
- Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI.
Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, Sánchez-González J, Macías A, Pérez-Asenjo B, Zamudio D, Alonso-Farto JC, España S, Mendiguren J, Bueno H, García-Ruiz JM, Ibañez B, Fernández-Ortiz A, Sanz J. Fernández-Friera L, et al. J Am Coll Cardiol. 2019 Apr 2;73(12):1371-1382. doi: 10.1016/j.jacc.2018.12.075. J Am Coll Cardiol. 2019. PMID: 30922468 - Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT.
Hetterich H, Rominger A, Walter L, Habs M, Volpers S, Hacker M, Reiser MF, Bartenstein P, Saam T. Hetterich H, et al. Int J Cardiovasc Imaging. 2016 Jan;32(1):49-59. doi: 10.1007/s10554-015-0660-8. Epub 2015 Apr 22. Int J Cardiovasc Imaging. 2016. PMID: 25898891 - Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study.
Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, Ibañez B, López-Melgar B, Laclaustra M, Oliva B, Mocoroa A, Mendiguren J, Martínez de Vega V, García L, Molina J, Sánchez-González J, Guzmán G, Alonso-Farto JC, Guallar E, Civeira F, Sillesen H, Pocock S, Ordovás JM, Sanz G, Jiménez-Borreguero LJ, Fuster V. Fernández-Friera L, et al. Circulation. 2015 Jun 16;131(24):2104-13. doi: 10.1161/CIRCULATIONAHA.114.014310. Epub 2015 Apr 16. Circulation. 2015. PMID: 25882487 - Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8.
Ibanez B, Fernández-Ortiz A, Fernández-Friera L, García-Lunar I, Andrés V, Fuster V. Ibanez B, et al. J Am Coll Cardiol. 2021 Jul 13;78(2):156-179. doi: 10.1016/j.jacc.2021.05.011. J Am Coll Cardiol. 2021. PMID: 34238438 Review. - Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement.
Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Huet P, et al. J Nucl Med. 2015 Apr;56(4):552-9. doi: 10.2967/jnumed.114.142596. Epub 2015 Feb 26. J Nucl Med. 2015. PMID: 25722452 Review.
Cited by
- Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study.
Fernández-Cidón B, Candás-Estébanez B, Gil-Serret M, Amigó N, Corbella E, Rodríguez-Sánchez MÁ, Padró-Miquel A, Brotons C, Hernández-Mijares A, Calmarza P, Jarauta E, Brea AJ, Mauri M, Guijarro C, Vila À, Valdivielso P, Corbella X, Pintó X. Fernández-Cidón B, et al. J Clin Med. 2021 Mar 29;10(7):1379. doi: 10.3390/jcm10071379. J Clin Med. 2021. PMID: 33805580 Free PMC article. - Imaging subclinical atherosclerosis: is it ready for prime time? A review.
Fernández-Friera L, Ibáñez B, Fuster V. Fernández-Friera L, et al. J Cardiovasc Transl Res. 2014 Oct;7(7):623-34. doi: 10.1007/s12265-014-9582-4. Epub 2014 Aug 14. J Cardiovasc Transl Res. 2014. PMID: 25119855 Review. - Bone marrow activation in response to metabolic syndrome and early atherosclerosis.
Devesa A, Lobo-González M, Martínez-Milla J, Oliva B, García-Lunar I, Mastrangelo A, España S, Sanz J, Mendiguren JM, Bueno H, Fuster JJ, Andrés V, Fernández-Ortiz A, Sancho D, Fernández-Friera L, Sanchez-Gonzalez J, Rossello X, Ibanez B, Fuster V. Devesa A, et al. Eur Heart J. 2022 May 14;43(19):1809-1828. doi: 10.1093/eurheartj/ehac102. Epub 2022 Mar 11. Eur Heart J. 2022. PMID: 35567559 Free PMC article. Clinical Trial. - Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease.
Istas G, Declerck K, Pudenz M, Szic KSV, Lendinez-Tortajada V, Leon-Latre M, Heyninck K, Haegeman G, Casasnovas JA, Tellez-Plaza M, Gerhauser C, Heiss C, Rodriguez-Mateos A, Berghe WV. Istas G, et al. Sci Rep. 2017 Jul 11;7(1):5120. doi: 10.1038/s41598-017-03434-0. Sci Rep. 2017. PMID: 28698603 Free PMC article. - PET imaging of inflammation in atherosclerosis.
Tarkin JM, Joshi FR, Rudd JH. Tarkin JM, et al. Nat Rev Cardiol. 2014 Aug;11(8):443-57. doi: 10.1038/nrcardio.2014.80. Epub 2014 Jun 10. Nat Rev Cardiol. 2014. PMID: 24913061 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical